Geron Corp reveals CEO is leaving

12 March 2025

California commercial-stage biopharma firm Geron Corporation (Nasdaq: GERN) has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025.

While a search for a new CEO with significant commercial experience is underway, the board of directors has appointed current board member Dawn Carter Bir as interim president and CEO, effective immediately. Additionally, Elizabeth O’Farrell has been appointed as chairperson.

No reason for the departure was given, but this news comes in the wake of a lackluster past few months for the launch of Rytelo (imetelstat), in LR-MDS). Geron has not provided a timeline for the hire of a new CEO,

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK